Core Viewpoint - Aethlon Medical, Inc. is set to release its financial results for the fiscal first quarter ending June 30, 2024, on August 14, 2024, and will host a conference call to discuss these results and recent corporate developments [1] Financial Results Announcement - Aethlon Medical will issue its financial results at 4:15 p.m. ET on August 14, 2024 [1] - A conference call will follow at 4:30 p.m. ET on the same day, including a question and answer session [1] Company Overview - Aethlon Medical focuses on developing the Hemopurifier, an immunotherapeutic device aimed at treating cancer and life-threatening viral infections [3] - The Hemopurifier has shown promise in human studies for removing life-threatening viruses and harmful exosomes from biological fluids [3] - The device is designated as a Breakthrough Device by the FDA for treating advanced or metastatic cancer and life-threatening viruses [3]

Aethlon Medical, Inc. (NASDAQ:AEMD) Q4 2024 Earnings Conference Call June 27, 2024 4:30 PM ET Company Participants Michael Miller - Rx Communications, IR James Frakes - Interim CEO and CFO Steven LaRosa - Chief Medical Officer Conference Call Participants Marla Marin - Zacks Operator Good day and welcome to the Aethlon Medical Fiscal Year End of 2024 Earnings Conference Call. All participants will be in a listen-only mode. [Operator Instructions] After today’s presentation there will be an opportunity to as ...

Financial Performance - For the fiscal year ended March 31, 2024, the company reported a net loss of $12,208,174, an increase from the net loss of $12,029,786 for the fiscal year ended March 31, 2023[292]. - Consolidated operating expenses for the fiscal year ended March 31, 2024 were $12,636,568, compared to $12,472,883 for the fiscal year ended March 31, 2023, reflecting an increase of $163,685[288]. - The company reported a significant increase in payroll and related expenses, primarily due to separation expenses for a former executive, totaling $861,994[289]. - In the fiscal year ended March 31, 2024, the company raised approximately $1,322,383 from the issuance of common stock, a significant decrease from $8,927,211 raised in the previous fiscal year[314]. - Net cash used in operating activities was approximately $10,130,000 in fiscal 2024, a slight decrease from $10,505,000 in fiscal 2023, primarily due to a positive change in working capital[311]. - The company expects to continue incurring increasing negative cash flows and net losses for the foreseeable future, necessitating further capital raises[305]. Cash and Working Capital - The company had a cash balance of $5,441,978 and working capital of $4,395,889 as of March 31, 2024, down from a cash balance of $14,532,943 and working capital of $13,585,478 at March 31, 2023[293]. - The company currently has over $9.1 million in cash and cash equivalents, but there is substantial doubt that this will sustain operations for 12 months beyond the filing date of the financial statements[307]. - The gross proceeds from a recent public offering were approximately $4.7 million, intended for general corporate purposes including clinical trial expenses and working capital[325]. - The company raised aggregate net proceeds of $8,927,211 in fiscal 2023, which was significantly higher than the $1,322,383 raised in fiscal 2024[303]. Clinical Trials and Product Development - The Hemopurifier has been designated as a "Breakthrough Device" by the FDA for oncology and life-threatening viral infections, with ongoing clinical trials planned in Australia and India[267][268]. - The company is investigating the Hemopurifier's potential applications in organ transplantation, focusing on removing harmful substances from recovered organs[281]. - The company has received ethics review board approval for clinical trials in India to treat severe COVID-19, with two sites currently involved[278][279]. - The company is working with North American Science Associates, LLC to manage planned clinical trials for the Hemopurifier in oncology indications in the U.S. and Australia[269]. - The company expects clinical trial expenses to increase for the foreseeable future, including costs related to manufacturing additional Hemopurifiers[304]. Market and Economic Conditions - The company plans to access equity markets for additional capital, but there is no assurance that this will be successful due to potential worsening global economic conditions[308]. - The average price per share for common stock sold under the 2022 ATM Agreement was $4.47 in fiscal 2024, compared to $11.93 in fiscal 2023[302][303]. - The company has $5,302,617 of 2022 ATM Shares remaining available for sale under the 2022 ATM Agreement as of March 31, 2024[298].

Exhibit 99.1 Aethlon Medical Announces Financial Results for the Fiscal Year Ended March 31, 2024 and Provides Corporate Update Conference Call to be Held Today at 4:30 p.m. ET SAN DIEGO, June 27, 2024 -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today reported financial results for its fiscal year ended March 31, 2024 and provided an update on recent developments. Company Updates Aethlon Medic ...

Core Viewpoint - Aethlon Medical, Inc. is advancing its Hemopurifier technology aimed at treating cancer and life-threatening infectious diseases, with recent clinical trial approvals and financial updates indicating progress in its operations and research initiatives [1][5]. Company Updates - Aethlon Medical is focused on the clinical development of its Hemopurifier, which is designed to remove harmful exosomes and viruses from blood, with applications in oncology and organ transplantation [2]. - The company received full ethics approval for a clinical trial of the Hemopurifier in cancer patients, valid until June 13, 2027, to be conducted in Australia [3]. - The Hemopurifier aims to improve response rates to anti-PD-1 therapies, as only about 30% of patients respond to treatments like pembrolizumab or nivolumab [4]. Financial Results - As of March 31, 2024, Aethlon Medical reported a cash balance of approximately $5.4 million, which increased to about $9.1 million by June 25, 2024 [8]. - Consolidated operating expenses for the fiscal year ended March 31, 2024, were approximately $12.6 million, a slight increase from $12.5 million in the previous year, primarily due to payroll increases [8][9]. - The net loss for the fiscal year ended March 31, 2024, was $12.2 million, compared to $12.0 million for the previous fiscal year [11]. Clinical Trials and Research - The company is progressing towards oncology trials in Australia and India, with expectations to enroll the first patient by the end of 2024 [5]. - Aethlon is also conducting a COVID-19 trial in India, with one patient treated so far, while monitoring a new COVID-19 subvariant [6]. - The Hemopurifier has shown potential in capturing previous strains of the H5N1 virus, although it has not been tested against the current strain [7].

Core Viewpoint - Aethlon Medical, Inc. is set to release its financial results for the fiscal year ending March 31, 2024, on June 27, 2024, and will host a conference call to discuss these results and recent corporate developments [1]. Financial Results Announcement - Aethlon Medical will issue its financial results at 4:15 p.m. ET on June 27, 2024 [1]. - A conference call will follow at 4:30 p.m. ET for management to review the financial results and recent developments [1]. - Interested parties can register for the conference call online or by phone [1]. Conference Call Details - The conference call will include a question and answer session after management's remarks [1]. - A replay of the call will be available approximately one hour after the call ends, accessible through the company's website or by specific phone numbers [2]. Company Overview - Aethlon Medical focuses on developing the Hemopurifier, an immunotherapeutic device aimed at treating cancer and life-threatening viral infections [3]. - The Hemopurifier has shown efficacy in removing life-threatening viruses and harmful exosomes in studies, with potential applications in cancer treatment [3]. - The device has received FDA Breakthrough Device designation for treating advanced or metastatic cancer and life-threatening viruses [3].

Industry Overview - The solid tumor therapeutics market is projected to grow from USD 222.71 billion in 2023 to USD 885.44 billion over the next decade, driven by increased pharmaceutical investments in R&D [1] - North America holds the largest share of the global solid tumor therapeutics market, accounting for 44% [1] Company Developments - Aethlon Medical, Inc. received full ethics approval for a clinical trial of its Hemopurifier® in cancer patients with solid tumors, valid until June 13, 2027 [2] - The trial aims to assess the safety, feasibility, and dose-finding of the Hemopurifier® in patients undergoing anti-PD-1 monotherapy, such as Keytruda® or Opdivo® [2][4] - Aethlon's Hemopurifier® is designed to remove extracellular vesicles (EVs) from the bloodstream, potentially improving response rates to anti-PD-1 therapies [3][11] Clinical Trial Insights - The trial will involve approximately 18 patients and will monitor safety and adverse events, as well as changes in EV concentrations [4] - Patients not responding to initial therapy will enter the Hemopurifier® treatment phase, receiving up to three treatments within a week [4] Competitive Landscape - Current therapies like Keytruda® and Opdivo® have a lasting clinical response rate of only about 30% [3] - AbbVie has made significant moves in the solid tumor market, including the acquisition of ImmunoGen to enhance its portfolio [8] - AbbVie is advancing a differentiated pipeline in solid tumors, showcasing its innovative antibody-drug conjugate (ADC) platform at ASCO 2024 [9] Research and Development Trends - Major pharmaceutical companies are heavily investing in R&D, with Roche expected to lead with USD 14 billion by 2026, followed by Johnson & Johnson and Merck & Co. [11] - Aethlon Medical's focus on tumor-derived exosomes addresses a significant unmet need in cancer care, highlighting the evolving understanding of exosomes in cancer treatment [11]

Core Viewpoint - Aethlon Medical has received full ethics approval for a clinical trial of its Hemopurifier® device aimed at cancer patients with solid tumors who are not responding to anti-PD-1 therapies, marking a significant milestone for the company [1][3]. Group 1: Clinical Trial Details - The Human Research Ethics Committee of the Central Adelaide Local Health Network approved the trial on June 13, 2024, which is valid for three years until June 13, 2027 [1]. - The trial will be conducted by Prof. Michael Brown at the Cancer Clinical Trials Unit, Royal Adelaide Hospital, and will focus on safety, feasibility, and dose-finding [1][3]. - The primary endpoint of the trial is safety, monitoring adverse events and lab test changes in approximately 18 patients with stable or progressive disease after a two-month run-in period of PD-1 antibody therapy [3]. Group 2: Mechanism and Rationale - Only about 30% of patients receiving pembrolizumab or nivolumab experience lasting clinical responses, with extracellular vesicles (EVs) from tumors contributing to cancer spread and resistance to therapies [2]. - The Hemopurifier is designed to bind and remove these EVs from the bloodstream, potentially improving therapeutic response rates to anti-PD-1 antibodies [2]. Group 3: Future Steps and Regulatory Path - Following the ethics approval, the company plans to submit to the Therapeutic Goods Administration and obtain approval from the CALHN Research Governance Committee [3]. - The company also intends to submit to additional Ethics Committees in Australia and India to facilitate further patient enrollment [3]. Group 4: Company Overview - Aethlon Medical focuses on developing the Hemopurifier, a clinical stage immunotherapeutic device aimed at treating cancer and life-threatening viral infections [4]. - The Hemopurifier has shown promise in removing harmful exosomes and life-threatening viruses, with FDA designations as a Breakthrough Device for advanced or metastatic cancer treatment [4].

Core Viewpoint - The resurgence of virus threats, particularly bird flu, has prompted increased interest in various treatment solutions, including those beyond vaccine development, with Aethlon Medical, Inc. at the forefront of innovative therapeutic approaches [1][2]. Company Developments - Aethlon Medical, Inc. is advancing its Hemopurifier® technology, which targets cancer-promoting exosomes and circulating viruses, and is preparing for phase 1 clinical trials focused on patients with solid tumors undergoing anti-PD-1 therapy [2][3]. - The Hemopurifier® has received FDA designation as a "Breakthrough Device" for treating advanced or metastatic cancer and life-threatening viral infections that lack approved therapies [3][4]. - Aethlon has previously explored the Hemopurifier®'s application in treating viral diseases, demonstrating its capability to capture various viruses, including HIV, hepatitis-C, and Ebola, in early studies [4]. Industry Trends - The current climate of heightened virus threats has led to a surge in interest from retail investors in stocks related to vaccine development, as evidenced by rising shares of vaccine manufacturers amid discussions of new vaccine programs for bird flu [5][9]. - ImmunityBio is also making strides in immunotherapy, with promising preclinical data suggesting that their combination therapy could manage HIV without the need for antiretroviral treatment [6][7]. - Aligos Therapeutics has reported positive results from its clinical trials for hepatitis B, showcasing complete suppression of HBV DNA in all subjects treated with their drug [8]. Market Sentiment - The increasing cases of bird flu are driving retail investors to seek out stocks with potential solutions, indicating a pattern of trading frenzies in response to emerging viral threats [9].

Group 1 - Aethlon Medical (NASDAQ:AEMD) stock is experiencing significant trading activity, with over 26 million shares exchanged, a substantial increase from its average daily volume of approximately 974,000 shares [1] - The company's float is around 2.56 million shares, indicating a limited supply available for trading [1] - AEMD is classified as a penny stock, with a prior closing price of 44 cents per share and a market capitalization of about $2.228 million [1] Group 2 - AEMD stock has surged by 82.4% as of Thursday morning, but it was down 79.8% year-to-date before this increase [2] - The lack of news or analyst coverage raises concerns about potential market manipulation, as penny stocks are often subject to "pump and dump" schemes [2] - Investors are advised to be cautious about investing in AEMD stock due to the volatility and the nature of penny stocks [2]